BioSpace News Archive

Nordic Bioscience, a leading biomarker company, today announced that the company’s extracellular matrix (ECM) biomarker, PRO-C3 (nordicPRO-C3™) will be available as a research use only (RUO) product in China at LabCorp.

Zomedica Corp. announced that it will be hosting a Virtual Investor Day event on Tuesday, February 13, 2024, starting at 3:00 p.m. ET.

Arvinas, Inc. and Pfizer Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation for the investigation of vepdegestrant for monotherapy in the treatment of adults with estrogen receptor positive/human growth epidermal growth factor 2 negative locally advanced or metastatic breast cancer previously treated with endocrine-based therapy.

Eli Lilly and Company announced its financial results for the fourth quarter of 2023.

Microbix Biosystems Inc. announces that it is presenting results of a Quality Assessment Product for supporting the clinical use and accuracy of molecular tests for infection with Helicobacter pylori, the bacterial cause of stomach ulcers, at Labquality Days, a lab diagnostics conference taking place in Helsinki, Finland from February 8 to 10, 2024.

ONL Therapeutics, Inc. announced that David Esposito, president and chief executive officer, will present a corporate update at the BIO CEO & Investor Conference on Tuesday, February 27 at 2:30 PM ET.

Olema Pharmaceuticals, Inc. announced that the Company will participate in the following upcoming investor conferences.

Kraig Biocraft Laboratories, Inc., announces the successful creation of a new recombinant spider silk hybrid.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”) announced today that it has concluded its interaction with the U.S. Food and Drug Administration (“FDA”) on optimizing the development plan for its stroke program which aims to evaluate the effects of cranial-nerve non-invasive neuromodulation (“CN-NINM”) delivered using PoNS Therapy® on gait and dynamic balance in chronic stroke survivors.

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development.